Bristol Myers Squibb is set to unveil groundbreaking clinical and real-world data from its cardiovascular portfolio at the esteemed European Society of Cardiology (ESC) Congress in Madrid, Spain, from August 29 to September 1, 2025. Among the highlights are new insights on Camzyos (mavacamten) in patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) and data from the BMS-Pfizer Alliance on Eliquis (apixaban). Dr. Roland Chen, Senior Vice President of Drug Development in immunology and cardiovascular medicines at Bristol Myers Squibb, emphasized the company’s 70-year legacy in cardiovascular medicine and its commitment to transforming patients’ lives. Camzyos, the first cardiac myosin inhibitor available, has shown promising results in clinical studies, offering symptom relief, improved functional capacity, and cardiac structure enhancements in patients with oHCM.
At the ESC Congress, Bristol Myers Squibb will present a range of key findings, including real-world outcomes for Camzyos in the treatment of symptomatic oHCM from the COLLIGO-HCM study, showcasing diverse patient populations across five countries. Additionally, there will be insights on the efficacy and safety of Camzyos monotherapy based on a pooled analysis of four phase 3 studies. A late-breaking presentation will reveal topline results from the ODYSSEY-HCM trial, the largest and longest-duration study to date in adult patients with symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM). Camzyos, approved as the first cardiac myosin inhibitor in the US and the EU, has received regulatory approvals in over 50 countries, making it a significant player in the treatment landscape for oHCM.
Camzyos, a selective and reversible allosteric inhibitor of cardiac myosin, exerts its effects by modulating the number of myosin heads involved in power generation, ultimately improving cardiac function in patients with oHCM. By reducing dynamic left ventricular outflow tract obstruction and enhancing cardiac filling pressures, Camzyos addresses key mechanistic hallmarks of HCM, leading to symptom alleviation and increased activity levels in affected individuals. On the other hand, Eliquis, an oral selective Factor Xa inhibitor developed by the Bristol Myers Squibb-Pfizer Alliance, works by inhibiting Factor Xa, a crucial protein in blood clotting. Eliquis has garnered approvals for various indications in the US, demonstrating efficacy and safety in reducing the risk of stroke, systemic embolism, deep vein thrombosis, pulmonary embolism, and venous thromboembolism in both adult and pediatric patients.
The mission of Bristol Myers Squibb is centered on discovering, developing, and delivering innovative medicines that empower patients to overcome serious diseases. The company’s relentless pursuit of cutting-edge science aims to redefine the boundaries of medical possibilities and enhance the quality of care for patients worldwide. By showcasing the latest advancements in cardiovascular medicine at the ESC Congress 2025, Bristol Myers Squibb underscores its dedication to improving patient outcomes and driving meaningful progress in the field of cardiology.
Takeaways:
– Bristol Myers Squibb is at the forefront of cardiovascular medicine, presenting novel data on Camzyos and Eliquis at ESC Congress 2025.
– Camzyos, the first cardiac myosin inhibitor, shows promising results in improving symptoms and cardiac function in patients with oHCM.
– Eliquis, a Factor Xa inhibitor, has received approvals for multiple indications, highlighting its efficacy and safety profile in diverse patient populations.
– Bristol Myers Squibb’s commitment to innovative science and patient-centric care underscores its leadership in transforming the landscape of cardiovascular medicine.
Tags: clinical trials, regulatory
Read more on pharmabiz.com